Mizuho Forecasts Strong Price Appreciation for Sabra Healthcare REIT (NASDAQ:SBRA) Stock
Mizuho raised its price target for Sabra Healthcare REIT (NASDAQ:SBRA) from $21 to $22, maintaining a "neutral" rating with a potential 7.33% upside. The REIT reported Q3 EPS of $0.11, missing the $0.16 consensus, but revenue of $249.57 million exceeded expectations, rising 31.4% year-over-year. Insider selling by the CEO and a director was noted, though institutional investors collectively own 99.40% of the stock.
Sabra Healthcare REIT (NASDAQ:SBRA) Director Michael Foster Sells 10,000 Shares of Stock
Sabra Healthcare REIT Director Michael Foster sold 10,000 shares of SBRA stock for $209,800 on November 11th, reducing his stake by 12.07%. The company reported quarterly earnings of $0.11 per share, missing estimates, but revenue increased 31.4% year over year to $249.57 million. Sabra also declared a quarterly dividend of $0.30 per share, representing a 5.8% yield, while analysts maintain a "Moderate Buy" rating with a $21.67 consensus price target.
Sabra Health Care REIT Director Michael J. Foster Announces Plan to Sell 10,000 Shares
Sabra Health Care REIT Director Michael J. Foster has filed a Form 144 notice, indicating his intent to sell 10,000 shares of the company's common stock. This transaction, valued at approximately $213,200, is expected to occur around November 11, 2026. Foster originally acquired these shares in 2010 as part of annual board service awards and currently holds 28,254 direct shares not subject to vesting.
Sabra Health Care REIT, Inc., to Attend Nareit’s REITworld 2026 Annual Conference
Sabra Health Care REIT, Inc. announced that its key executives, including Chair and CEO Rick Matros, CFO Michael Costa, CIO Darrin Smith, and EVP of Finance Lukas Hartwich, will attend Nareit’s REITworld 2026 Annual Conference. The conference is scheduled from November 16-19, 2026, in Atlanta, Georgia. Sabra Health Care REIT is a Maryland corporation that operates as a self-administered, self-managed real estate investment trust focused on the healthcare industry across the United States and Canada.
Sabra Healthcare REIT (NASDAQ:SBRA) Stock Rated Strong-Buy in New Coverage at Huntington Sec
Huntington Sec initiated coverage on Sabra Healthcare REIT (NASDAQ:SBRA) with a "strong-buy" rating. This new rating follows other analyst reports, with the stock currently holding an average rating of "Moderate Buy" and a consensus price target of $21.50. The company recently reported mixed Q3 2026 earnings, missing EPS estimates but exceeding revenue expectations, and also increased its 2026 guidance.
Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) Stock to Pay Quarterly Dividend of $0.30
Sabra Healthcare REIT (NASDAQ:SBRA) announced a quarterly dividend of $0.30 per share, payable on November 30th to shareholders of record on November 13th, representing a 6.0% annual yield. Despite missing EPS estimates at $0.11, the company saw a 31.4% year-over-year revenue increase and raised its 2026 earnings guidance. Analysts anticipate Sabra will cover its dividend in the coming year, projecting $1.60 EPS against a $1.20 annual dividend.
Earnings call transcript: Sabra Health Care REIT tops revenue in Q3 2026, lifts outlook
Sabra Health Care REIT (SBRA) reported Q3 2026 revenue of $249.56 million, exceeding Wall Street expectations, and raised its full-year outlook despite missing EPS forecasts. The company's senior housing operating portfolio (SHOP) continued to drive growth, with cash NOI increasing and occupancy improving. Sabra aims to increase SHOP exposure to 50% by year-end 2027 while reducing skilled nursing exposure, and management expects 7%-8% year-over-year earnings growth at the midpoint of its 2026 guidance.
A $300M mortgage loan ends with a reduced cash repayment for Sabra Health Care REIT (SBRA).
Sabra Health Care REIT (SBRA) reported its third-quarter 2026 financial results, which included a significant $100 million write-off related to a $300 million Recovery Centers of America mortgage loan that was satisfied with a reduced $200 million cash payment. Despite this write-off and a $104.6 million loan-loss provision, the company saw an increase in third-quarter revenue to $249.6 million and net income attributable to Sabra of $28.6 million, compared to the previous year. Sabra also acquired 14 senior housing operating portfolio (SHOP) communities and two skilled nursing facilities, while declaring a quarterly cash dividend of $0.30 per share.
Sabra Raises 2026 FFO Outlook as Same-Property Senior Housing Cash NOI Climbs 14.6%
Sabra Health Care REIT, Inc. has raised its 2026 funds from operations (FFO) outlook after a strong third quarter saw same-property cash net operating income (NOI) in its Senior Housing Operating Portfolio increase by 14.6% year over year. The company reported higher revenue and net income, alongside an increase in its FFO and AFFO guidance ranges for the full year, despite a lowered net income outlook. Sabra also completed the transfer of 26 properties, which led to an increase in annualized cash rent.
79,800 Sabra Healthcare REIT, Inc. $SBRA Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al
Virginia Retirement Systems has reduced its stake in Sabra Healthcare REIT, Inc. (SBRA) by 25.8%, selling 79,800 shares and retaining 230,053 shares valued at $4.54 million. Despite this, institutional investors collectively own 99.4% of SBRA, and analysts maintain a "Moderate Buy" rating with an average price target of $21.50. The company's latest quarterly revenue saw a 24.7% year-over-year increase, though it missed EPS expectations.
Sabra Health Care REIT, Inc. (SBRA) Seasonal returns chart
This article presents a seasonal returns chart for Sabra Health Care REIT, Inc. (SBRA), showing the average monthly price return from 2016 to 2026. It indicates that SBRA's Q3 2026 earnings call is scheduled for November 3, 2026. The article is primarily a data visualization tool with minimal descriptive text.
Sabra Health Care REIT, Inc. (SBRA) stock price, news, quote and history
This article provides a detailed overview of Sabra Health Care REIT, Inc. (SBRA) stock, including its current price, historical performance, and key financial metrics. It covers market data, analyst ratings, earnings trends, and valuation measures, positioning SBRA as a self-administered real estate investment trust focused on healthcare facilities.
Sabra Healthcare REIT (SBRA) Projected to Announce Quarterly Earnings on Monday
Sabra Healthcare REIT (SBRA) is expected to announce its Q3 2026 earnings after market close on Monday, November 2nd, with analysts forecasting EPS of $0.1637 and revenue of $236.64 million. The company's prior quarter reported a loss per share but exceeded revenue expectations, with shares currently yielding 6.1% from its $0.30 quarterly dividend. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $21.50.
Sabra Health Care REIT (NasdaqGS:SBRA) Stock Price
Sabra Health Care REIT (SBRA) is currently trading at US$19.74, appearing 13.4% undervalued compared to its US$22.79 fair value. The company's performance is supported by managed senior housing expansion, portfolio recycling, and a healthy balance sheet, despite a slight risk with moderate growth potential. Recent updates highlight strong Q2 results, strategic acquisitions, and a sustainable 5.85% dividend yield, though dividend increases are not anticipated during its acquisition phase.
Sabra Healthcare REIT Q3 2026 Earnings Date and Estimates
Sabra Healthcare REIT (SBRA) is scheduled to report its Q3 2026 earnings on Monday, November 2, 2026, after market close, with a conference call set for November 3rd at 1:00 PM ET. Analysts anticipate earnings of $0.1637 per share on $236.64 million in revenue. This forecast represents a significant decline in EPS compared to the prior year but an increase in revenue.
Wells Fargo cuts target for Sabra Health Care REIT stock to USD 21.00
Wells Fargo has reduced its price target for Sabra Health Care REIT (SBRA) from USD 23.00 to USD 21.00, while maintaining an "Overweight" rating. This adjustment comes as Sabra reported a 24.70% year-over-year revenue increase to USD 230.11 million for Q2 2026, despite a net loss of USD 25.25 million. The company is set to release its Q3 2026 results on November 2, 2026.
Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) Stock Has Consensus Target Price of $21.50 According to Brokerages
Sabra Healthcare REIT (NASDAQ:SBRA) has a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $21.50. Despite missing EPS estimates with a $0.10 per share loss against an expected $0.17 gain, the company's revenue increased by 24.7% year-over-year to $230.11 million, surpassing estimates. Sabra also maintains a high dividend yield of 6.3% ($1.20 annually), though its payout ratio is notably high at 461.54%.
Sabra Healthcare REIT Is Maintained at Overweight by Wells Fargo
This article reports that Wells Fargo has maintained its "Overweight" rating on Sabra Healthcare REIT. The report does not provide further details or analysis, only stating the analyst's reiterated stance.
Sabra Health Care REIT, Inc. Announces Third Quarter 2026 Earnings Release Date and Conference Call
Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced it will release its 2026 third-quarter earnings on November 2, 2026, after market close. The company will host a conference call and webcast to discuss the results on Tuesday, November 3rd, at 10:00 a.m. Pacific Time. Dial-in details and webcast URL were provided for interested participants.
Sabra Healthcare REIT (NASDAQ:SBRA) Price Target Cut to $21.00 by Analysts at Wells Fargo & Company
Wells Fargo & Company analysts have reduced their price target for Sabra Healthcare REIT (NASDAQ:SBRA) from $23.00 to $21.00, while maintaining an "overweight" rating. This implies a potential upside of 9.80% from its current trading price. The company recently reported a significant EPS miss but exceeded revenue expectations, and the stock was trading down 1.1% in mid-day trading.
Sabra Health Care REIT, Inc. (SBRA) Stock forecasts
The article provides a brief overview of Sabra Health Care REIT Inc. (SBRA), identifying it as a healthcare facility real estate investment trust. It highlights an "All / Quantitative Report" from Argus dated October 14, 2026, which discusses SBRA. The current price is listed at $19.36, and the report is available for download.
UBS cuts target for Sabra Health Care REIT stock to USD 20.00
UBS has lowered its price target for Sabra Health Care REIT (SBRA) from $21.00 to $20.00, maintaining a Neutral rating. Despite this, Sabra reported a 24.70 percent increase in Q2 2026 revenue, exceeding expectations, though diluted earnings per share were negative. The stock closed at $19.34 on October 16, 2026, and its next earnings date is scheduled for November 9, 2026.
Barclays cuts Sabra Health Care REIT stock target to USD 21.00
Barclays has lowered its price target for Sabra Health Care REIT (SBRA) from USD 23.00 to USD 21.00, while maintaining an "Equal Weight" rating. The company's stock was trading at USD 19.37 on Nasdaq as of October 15, 2026, and is set to report its third-quarter results on November 4, 2026. Sabra Health Care REIT, which specializes in healthcare real estate, reported second-quarter revenues of USD 230.11 million and diluted EPS of minus USD 0.10.
Sabra Healthcare REIT Is Maintained at Equal-Weight by Barclays
Barclays has maintained its Equal-Weight rating for Sabra Healthcare REIT. The specific reasons for this rating were not provided in the document. This indicates that Barclays believes the stock will perform in line with the broader market or its sector.
Barclays Issues Pessimistic Forecast for Sabra Healthcare REIT (NASDAQ:SBRA) Stock Price
Barclays has lowered its price target for Sabra Healthcare REIT (NASDAQ:SBRA) from $23.00 to $21.00, while maintaining an "equal weight" rating, suggesting a 9.29% upside. Despite this, analyst sentiment remains a "Moderate Buy" with an average target of $21.69. The company reported strong revenue growth but missed adjusted earnings estimates, and CEO Richard Matros recently sold 200,000 shares.
80,453 Sabra Healthcare REIT, Inc. $SBRA Shares Acquired by Sound Income Strategies LLC
Sound Income Strategies LLC significantly increased its stake in Sabra Healthcare REIT, Inc. (SBRA), acquiring an additional 80,453 shares, bringing their total to over 1 million shares valued at approximately $19.8 million. This acquisition highlights institutional confidence in SBRA, as institutional investors now own 99.4% of the company. Despite missing consensus EPS estimates in its last quarterly report, Sabra Healthcare REIT maintains a "Moderate Buy" rating from analysts and offers an attractive 6.3% annualized dividend yield.
Sabra Healthcare REIT Q3 2026 Earnings Date and Estimates
Sabra Healthcare REIT (SBRA) is scheduled to report its Q3 2026 earnings on Wednesday, November 4, 2026, after market close, with a conference call at 4:00 PM ET. Analysts anticipate earnings of $0.1674 per share on revenue of $233.99 million. This forecast represents a significant year-over-year decrease in EPS but an increase in revenue compared to Q3 2025.
Huntington initiated coverage of Sabra Health Care REIT stock
Huntington has initiated coverage of Sabra Health Care REIT (SBRA) with an Outperform rating and a $23.00 price target. This decision follows Sabra's second-quarter 2026 revenue of $235.9 million, a 24.7% increase year-over-year, despite diluted earnings per share being negative $0.10. The company's guidance for 2026 normalized FFO of $1.53-$1.55 per diluted share suggests a 7% growth at the midpoint, highlighting the importance of this metric for valuation despite recent net losses.
Sabra Health Care REIT stock gets a fresh valuation review
Sabra Health Care REIT (SBRA) recently received a fresh valuation review on October 4, 2026, setting its fair value at USD 22.79, with an emphasis on managed senior housing, portfolio recycling, and balance sheet flexibility. Despite strong Q2 2026 same-store revenue growth of 8.6 percent, the company reported a negative adjusted EPS, missing consensus estimates. Analysts maintain a "Moderate Buy" consensus with an average price target of USD 22.23, significantly above its current Nasdaq price.
Sabra Health Care REIT stock carries a 6.1 percent yield
Sabra Health Care REIT's stock (SBRA) closed at USD 19.16 on October 2, 2026, offering a 6.1 percent annualized dividend yield despite a Q2 2026 diluted EPS loss of USD 0.10. While revenue grew 24.7 percent year-over-year, analysts maintain a "Moderate Buy" consensus with an average 12-month price target of USD 22.23, indicating potential upside for the stock which trades below its yearly high. The company's maintained FFO and AFFO guidance provides a positive outlook for investors.
Sabra Health Care REIT stock stood at EUR 17.25
Sabra Health Care REIT's stock was at EUR 17.25 on TradeGate as of September 25, 2026, with a market capitalization of USD 5.0 billion. Despite a 24.70% increase in Q2 2026 revenue, the company reported an earnings miss, while its FFO guidance for 2026 remains key for valuation. Analysts currently have a "Moderate Buy" consensus for the stock, with a 12-month target price above its Nasdaq price.
Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) Stock Rated "Moderate Buy" by Wall Street Brokerages
Sabra Healthcare REIT (NASDAQ:SBRA) has received a "Moderate Buy" rating from Wall Street brokerages, with seven out of fourteen analysts recommending a buy and the remaining seven suggesting a hold. The average 12-month price target is $22.23, exceeding its recent price of $19.77. Despite missing earnings expectations with a reported loss of ($0.10) per share, the company's quarterly revenue increased by 24.7% year-over-year to $230.11 million, and it maintains a high institutional ownership of 99.40%.
Sabra Healthcare REIT, Inc. $SBRA Stock Sold by Squarepoint Ops LLC
Squarepoint Ops LLC significantly reduced its holdings in Sabra Healthcare REIT (SBRA) by 93.6% in the second quarter, selling 157,633 shares and retaining 10,868 shares. Despite missing EPS estimates, Sabra's revenue rose 24.7% year-over-year, and the company maintains a quarterly dividend of $0.30 per share, reflecting a 6.1% annualized yield. Institutional investors hold 99.4% of SBRA, with analysts giving it a "Moderate Buy" rating and an average price target of $22.23.
NewEdge Advisors LLC Has $1.39 Million Position in Sabra Healthcare REIT, Inc. $SBRA
NewEdge Advisors LLC significantly increased its stake in Sabra Healthcare REIT (NASDAQ:SBRA) by 261.2% in the second quarter, bringing its total holdings to 71,128 shares valued at $1.39 million. Institutional investors collectively own 99.4% of the company, which holds a "Moderate Buy" consensus rating from analysts with an average price target of $22.23. Despite missing EPS estimates, Sabra reported a 24.7% year-over-year revenue increase and recently paid a quarterly dividend of $0.30, yielding 6.1% annually.
Sabra Health Care REIT stock holds firm as income metrics stay in focus
Sabra Health Care REIT's stock is trading near $19.74, with a market capitalization of approximately $5.043 billion, reflecting its stable rental income from healthcare facilities. The company's focus on long-term leases in skilled nursing and senior housing provides consistent funds from operations, making it an income-oriented investment. While demographic trends support demand, interest rate movements and regulatory changes remain key risk factors.
Sabra Healthcare REIT (NASDAQ:SBRA) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?
Sabra Healthcare REIT (NASDAQ:SBRA) saw its shares briefly exceed its 200-day moving average, reaching $20.42 before closing at $20.15. The company reported a quarterly earnings miss but revenue beat expectations, and it maintains a $0.30 quarterly dividend despite a high payout ratio. Analysts have a "Moderate Buy" rating, and CEO Richard Matros recently sold a significant block of shares.
Sabra Healthcare REIT (NASDAQ:SBRA) Now Covered by Huntington
Huntington has initiated coverage on Sabra Healthcare REIT (NASDAQ:SBRA) with an "outperform" rating and a $23 price target, signaling a potential 10.6% upside. The company currently holds a consensus "Moderate Buy" rating from analysts, with an average price target of $22.23. Despite reporting mixed quarterly results—revenue exceeding estimates but adjusted EPS missing—and CEO Richard Matros selling a significant number of shares, the overall analyst sentiment remains positive.
Engineers Gate Manager LP Trims Position in Sabra Healthcare REIT, Inc. $SBRA
Engineers Gate Manager LP significantly reduced its stake in Sabra Healthcare REIT (NASDAQ:SBRA) by 55.5% during the second quarter, selling 1.31 million shares and retaining 1.05 million shares valued at $20.5 million. Despite this, institutional investors still hold 99.4% of SBRA's outstanding stock. Sabra reported quarterly revenue exceeding estimates but missed EPS forecasts, while maintaining a quarterly dividend of $0.30, representing a 5.8% yield.
CEO of Sabra (NASDAQ: SBRA) lines up $4.15M stock sale
Sabra Health Care REIT, Inc. (SBRA) CEO, Richard K. Matros, has filed a Rule 144 notice to sell up to 200,000 shares of common stock through Merrill Lynch, valued at $4.15 million. The sales are anticipated to commence around September 8, 2026, and are tied to Restricted Stock Units granted between 2013 and 2017. This filing indicates a planned disposal of shares by an insider, which is common as RSUs vest.
Sabra Health Care REIT, Inc., Issues Business Update and will Participate in the BofA Securities 2026 Global Real Estate Conference
Sabra Health Care REIT, Inc. has released a business update for investors and will be participating in the BofA Securities 2026 Global Real Estate Conference. Key company executives, including the Chair and CEO Rick Matros and CFO Michael Costa, will represent Sabra at the event in New York from September 15-17, 2026. The company, a self-administered REIT, focuses on owning and investing in real estate for the healthcare industry across the U.S. and Canada.
Sabra Health Care CEO Matros sells $4.17m in stock By Investing.com
Richard K. Matros, CEO of Sabra Health Care REIT, Inc. (NASDAQ:SBRA), sold 200,000 shares worth approximately $4.17 million on September 8, 2026, under a Rule 10b5-1 trading plan. Despite the sale, the stock is considered slightly undervalued with a 5.77% dividend yield and a 14.73% year-to-date return. The company recently reported mixed Q2 2026 results with revenue exceeding forecasts but an adjusted net loss, though normalized cash flows improved, leading to an upgraded rating from Raymond James.
Sabra Healthcare REIT (NASDAQ:SBRA) CEO Sells 200,000 Shares
Sabra Healthcare REIT (NASDAQ:SBRA) CEO Richard Matros sold 200,000 shares worth approximately $4.17 million, reducing his ownership by 10.77% to 1.66 million shares. The transaction, executed under a Rule 10b5-1 plan, occurred as the company reported a quarterly loss despite revenue growth. Analysts currently maintain a consensus "Hold" rating for SBRA with a price target of $22.17.
Sabra Health Care CEO Matros sells $4.17m in stock
Richard K. Matros, CEO of Sabra Health Care REIT, Inc., sold 200,000 shares of company stock for approximately $4.17 million on September 8, 2026, pursuant to a pre-arranged trading plan. This transaction occurred amidst mixed financial results for Sabra Health Care in Q2 2026, where revenue beat expectations but the company reported an adjusted net loss due to a loan-loss provision. Despite this, management reaffirmed its full-year guidance, and Raymond James upgraded the stock to Market Perform.
309,853 Shares in Sabra Healthcare REIT, Inc. $SBRA Purchased by VIRGINIA RETIREMENT SYSTEMS ET Al
Virginia Retirement Systems acquired 309,853 shares of Sabra Healthcare REIT (NASDAQ:SBRA) valued at approximately $6.05 million during the second quarter, bringing institutional ownership in the company to 99.40%. Despite reporting a 24.7% year-over-year revenue increase to $230.11 million, Sabra missed EPS estimates with a negative $0.10. The company maintains a quarterly dividend of $0.30 per share and analysts currently rate the stock as a "Hold" with an average price target of $22.17.
Sabra Health Care REIT, Inc., Issues Business Update and will Participate in the BofA Securities 2026 Global Real Estate Conference
Sabra Health Care REIT, Inc. (Nasdaq: SBRA) has released a business update for investors and announced its participation in the BofA Securities 2026 Global Real Estate Conference. Key executives, including CEO Rick Matros, CFO Michael Costa, CIO Darrin Smith, and EVP of Finance Lukas Hartwich, will represent the company at the conference from September 15-17, 2026, in New York. Sabra is a real estate investment trust focused on the healthcare industry across the United States and Canada.
Hsbc Holdings PLC Boosts Holdings in Sabra Healthcare REIT, Inc. $SBRA
HSBC Holdings PLC significantly increased its stake in Sabra Healthcare REIT (SBRA) by 33.8% in the second quarter, now owning 676,554 shares valued at $13.3 million. Despite a quarterly loss of $0.10 per share, missing earnings estimates, the company's revenue rose 24.7% year-over-year to $230.1 million. Analysts have a "Hold" rating on SBRA, with a consensus price target of $22.17, and the REIT maintains a quarterly dividend of $0.30 per share, yielding 5.8%.
Readystate Asset Management LP Makes New $1.40 Million Investment in Sabra Healthcare REIT, Inc. $SBRA
Readystate Asset Management LP has made a new $1.40 million investment in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA), acquiring 71,748 shares. Despite the new institutional investment and other hedge funds increasing their stakes, analyst sentiment for SBRA remains mixed, with a consensus "Hold" rating and an average price target of $22.17. The company reported quarterly revenue above estimates but missed EPS expectations, and it maintains a 5.8% dividend yield with a high payout ratio.
Headlands Technologies LLC Has $1.32 Million Position in Sabra Healthcare REIT, Inc. $SBRA
Headlands Technologies LLC significantly increased its stake in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) by 333.1% in the second quarter, bringing its total holdings to 67,486 shares valued at approximately $1.32 million. Institutional investors and hedge funds collectively own 99.4% of SBRA, indicating strong institutional interest. Despite mixed analyst ratings, the company maintains a "Hold" consensus with a target price of $22.17 and offers a 5.9% annualized dividend yield.
Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) Given Average Rating of "Moderate Buy" by Brokerages
Sabra Healthcare REIT (NASDAQ:SBRA) has received a consensus "Moderate Buy" rating from thirteen brokerages, with an average 12-month price target of $22.27, exceeding its current share price of $20.61. Institutional investors hold a significant 99.40% stake and have recently increased their positions. Despite a 24.7% year-over-year revenue increase in its latest quarter, the company missed analyst earnings expectations and declared a quarterly dividend of $0.30 per share, resulting in a 5.8% yield.
Sabra Healthcare REIT (NASDAQ:SBRA) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened
Sabra Healthcare REIT (NASDAQ:SBRA) shares recently traded above their 200-day moving average, closing at $20.61 with a trading volume of over 1.6 million shares. Despite reporting a quarterly EPS of negative $0.10, missing estimates, the company saw a 24.7% year-over-year revenue increase and declared a quarterly dividend of $0.30 per share. Analyst sentiment remains largely positive, with a "Moderate Buy" consensus and an average price target of $22.27.